Comparative Pharmacology
Head-to-head clinical analysis: MYCELEX 7 versus POSACONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCELEX 7 versus POSACONAZOLE.
MYCELEX-7 vs POSACONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Posaconazole inhibits fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis, disrupting fungal cell membrane integrity and function.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily at bedtime for 7 days.
300 mg orally twice daily on day 1, then 300 mg once daily thereafter. Extended-release tablets: 300 mg orally twice daily on day 1, then 300 mg once daily. Intravenous: 300 mg IV twice daily on day 1, then 300 mg once daily.
None Documented
None Documented
Clinical Note
moderatePosaconazole + Tranilast
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast."
Clinical Note
moderatePosaconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Tolfenamic acid."
Clinical Note
moderatePosaconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide."
Clinical Note
moderateThe systemic half-life of clotrimazole following vaginal administration is approximately 0.5–1 hour due to rapid metabolism and elimination. This short half-life reflects minimal systemic absorption (3–10%).
Terminal elimination half-life: 35 hours (range 25–50 hours), allowing once-daily dosing after steady state; prolonged in hepatic impairment.
Primarily via feces as unchanged drug (approx. 50%) and metabolites. Renal excretion of unchanged drug is minimal (<1%) as the drug is poorly absorbed from the vagina. Biliary excretion contributes to fecal elimination.
Fecal (77% as unchanged drug) and renal (14% as glucuronide conjugates); <1% excreted unchanged in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal
Posaconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronic acid."